Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 5;8(60):34331-34342.
doi: 10.1039/c8ra04773a. eCollection 2018 Oct 4.

Semi-synthesis, structural modification and biological evaluation of 5-arylbenzofuran neolignans

Affiliations

Semi-synthesis, structural modification and biological evaluation of 5-arylbenzofuran neolignans

Ding Lin et al. RSC Adv. .

Abstract

5-Arylbenzofuran neolignans, a newfound class of natural products, were reported to possess several kinds of pharmacological activities. To solve the lack of natural sources and promote the research of 5-arylbenzofuran neolignans in all fields, an available semi-synthesis methodology of 5-arylbenzofuran neolignans was developed, and a detailed structural modification was conducted. In the meantime, a one-pot process of Waker-type cyclization and Wacker-type oxidation was developed. To explore the potential of 5-arylbenzofuran neolignans as bioactive substances, 5-arylbenzofuran neolignans and their derivatives were evaluated for their cytotoxicity. As a result, a preliminary structure-activity relationship was obtained. Most derivatives revealed low cytotoxic effects suggesting that they were relatively safer than the natural 5-arylbenzofuran neolignan. Several derivatives showed high cytotoxicities which were found to be closely associated with apoptosis-inducing. The selectivity assay for cytotoxicity showed tumor cells were more sensitive to the promising compounds than normal cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. The comparison of 5-arylbenzofuran neolignans with 2-arylbenzofuran neolignans, and the semi-synthesis methodology and structural modification of 5-arylbenzofuran neolignans.
Scheme 1
Scheme 1. Reagents and conditions: (a) PdCl2, NaOAc, O2, DMA/H2O, 60 °C; (b) H2SO4, DCE, 50 °C; (c) NaBH4, NiCl2·6H2O, EtOH, r.t.; (d) Pd/C, H2, MeOH, reflux; (e) CH3I, KOH, THF, r.t.
Scheme 2
Scheme 2. Reagents and conditions: (a) NBS, MeCN, r.t.; (b) HNO3, HOAc, CH2Cl2, 0 °C; (c) NaNO2, concentrated hydrochloric acid (36–38%), MeCN/H2O, r.t.; (d) secondary amines, HCHO(37%), MeOH, 60 °C; (e) Zn, NH4Cl, HOAc, EtOH/H2O, r.t.; (f) Pd/C, H2, MeOH, reflux.
Scheme 3
Scheme 3. Reagents and conditions: (a) CH3I, NaOAc, DMF, r.t.; (b) acetic anhydride, K2CO3, ethyl acetate, r.t.; (c) acryloyl chloride, K2CO3, CH2Cl2, r.t.; (d) chloroacetyl chloride or oxalyl chloride, DMAP, NEt3, THF, r.t. to reflux; (e) benzaldehyde, acetic acid, EtOH, r.t.; (f) chloroacetyl chloride, K2CO3, CH2Cl2, r.t.; (g) secondary amines, NEt3, THF, r.t.
Scheme 4
Scheme 4. Reagents and conditions: (a) PdCl2, O2, DMA/H2O, 60 °C; (b) R–NH2, EtOH, r.t.; (c) NaBH4, EtOH, r.t.
Fig. 2
Fig. 2. (A) Cellular morphologies of HepG2 cells treated with different compounds (1, 23, 30) for 24 h. (B) Images of Hoechst 33258 stained HepG2 cells which were treated with 20 μM of different compounds (1, 23, 30) for 24 h. The arrows indicated the apoptotic cell. Original magnification is 400×.
Fig. 3
Fig. 3. Apoptosis effect of compounds 1, 23 and 30 at 20 μM in HepG2 cells for 24 h. The cells were stained with Annexin V-FITC/P and followed by flow cytometry analysis.
Fig. 4
Fig. 4. mRNA expression levels of (A) caspase-3, caspase-9, (B) Bax, Bcl-2, (C) p53 and p21 in HepG2 cells treated with 20 μM of different compounds (1, 23, 30) for 24 h. *P < 0.05, **P < 0.01.

Similar articles

Cited by

References

    1. Apers S. Vlietinck A. Pieters L. Phytochem. Rev. 2003;2:201–217. doi: 10.1023/B:PHYT.0000045497.90158.d2. - DOI
    1. Kim J. K. Jun J. G. J. Cell. Biochem. 2011;112:3816–3823. doi: 10.1002/jcb.23312. - DOI - PubMed
    1. Setzer M. S. Byler K. G. Ogungbe I. V. Setzer W. N. Sci. Pharm. 2017;85:5–32. doi: 10.3390/scipharm85010005. - DOI - PMC - PubMed
    1. Morikawa T. Hachiman I. Matsuo K. Nishida E. Ninomiya K. Hayakawa T. Yoshie O. Muraoka O. Nakayama T. J. Nat. Prod. 2016;79:2005–2013. doi: 10.1021/acs.jnatprod.6b00262. - DOI - PubMed
    1. Barros L. F. L. Barison A. Salvador M. J. Mello-Silva R. D. Cabral E. C. Eberlin M. N. Stefanello M. E. A. J. Nat. Prod. 2009;72:1529–1532. doi: 10.1021/np900203y. - DOI - PubMed